Xspray Pharma

Board/Management Information • Feb 7, 2024

Xspray Pharma appoints Michael af Winklerfelt as acting CFO

Xspray Pharma has appointed Michael af Winklerfelt as acting CFO, beginning tomorrow, February 8th. The company's current CFO Kerstin Hasselgren leaves the role at her own request and will transition to another internal role as Senior Advisor and Head of IR.

Michael af Winklerfelt has extensive experience from similar roles at listed life science companies, most recently at Prostatype Genomics. He also has extensive experience from international assignments and has an MSc from Stockholm School of Economics and an MBA from Emory University. Michael af Winklerfelt will replace Kerstin Hasselgren who has been the company's CFO since 2019 and who now leaves the role at her own request due to personal reasons. Kerstin Hasselgren will remain in the company as Head of IR and Senior Advisor to management.

"I am glad to welcome Michael af Winklerfelt to Xspray in an intensive stage of our transition from a research company to a commercial company with our first product launch planned for September this year. I also want to thank Kerstin Hasselgren for her valuable contributions as CFO and also look forward to continuing to benefit from her vast experience of the industry and competence in her new role as Senior Advisor," says Per Andersson, CEO of Xspray Pharma.

Michael af Winklerfelt will until further notice be acting CFO and will begin in his role tomorrow, on February 8, 2024.

For further information, please contact:

Per Andersson Chief Executive Officer Xspray Pharma AB Mob: +46 (0) 70 688 23 48 E-mail: per.andersson@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with numerous product candidates in clinical development, utilizing its innovative, patented HyNap-technology to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology segment often with high drug prices. The company's goal is to become a market leader of enhanced PKIs for cancer treatment. Xspray Pharma's primary drug candidate, Dasynoc (XS004-dasatinib), is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose because of better solubility profile. Its compatibility with proton pump inhibitors (PPIs), commonly co-prescribed to chronic myeloid leukemia patients, provides a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®).

Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com

Attachments

Xspray Pharma appoints Michael af Winklerfelt as acting CFO